The effect of organic anion-transporting polypeptides 1B1, 1B3 and 2B1 on the antitumor activity of flavopiridol in breast cancer cells

International Journal of Oncology

Volumn 46, Issue 1, 2015, Pages 324-332

  Brenner, Stefan ^a   Riha, Juliane ^a   Giessrigl, Benedikt ^a   Thalhammer, Theresia ^b   Grusch, Michael ^b   Krupitza, Georg ^b   Stieger, Bruno ^c   Jäger, Walter ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Breast cancer; Cell cycle inhibition; Cellular uptake; Flavopiridol; OATP; Transport

Indexed keywords

ANTINEOPLASTIC AGENT; FLAVONOID; FLAVOPIRIDOL; ORGANIC ANION TRANSPORTER; PIPERIDINE DERIVATIVE; SLCO1B1 PROTEIN, HUMAN; SLCO1B3 PROTEIN, HUMAN; SLCO2B1 PROTEIN, HUMAN;

ANIMAL; BREAST TUMOR; CHO CELL LINE; CRICETULUS; FEMALE; HAMSTER; HUMAN; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; FLAVONOIDS; HUMANS; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; PIPERIDINES;

EID: 84917707385     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2731     Document Type: Article

References (51)

1. Carlson B, Lahusen T, Singh S, et al: Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res 59: 4634-4641, 1999.
2. Sedlacek HH, Czech J, Naik R, et al: Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int J Oncol 9: 1143-1168, 1996.
3. Czech J, Hoffmann D, Naik R and Sedlacek HH: Antitumoral activity of flavone L-86-8275. Int J Oncol 6: 31-36, 1995.
4. Lam LT, Pickeral OK, Peng AC, et al: Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2: Research0041, 2001.
5. Reiner T, de las Pozas A and Perez-Stable C: Sequential combinations of flavopiridol and docetaxel inhibit prostate tumors, induce apoptosis, and decrease angiogenesis in the Ggamma/T-15 transgenic mouse model of prostate cancer. Prostate 66: 1487-1497, 2006.
6. Jung CP, Motwani MV and Schwartz GK: Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer Res 7: 2527-2536, 2001.
7. Byrd JC, Lin TS, Dalton JT, et al: Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109: 399-404, 2007.
8. Phelps MA, Lin TS, Johnson AJ, et al: Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 113: 2637-2645, 2009.
9. Byrd JC, Peterson BL, Gabrilove J, et al: Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from cancer and leukemia group B study 19805. Clin Cancer Res 11: 4176-4181, 2005.
10. Lin TS, Ruppert AS, Johnson AJ, et al: Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 27: 6012-6018, 2009.
11. Hagenauer B, Salamon A, Thalharmmer T, et al: In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: involvement of udpglucuronosyltransferases 1A1 and 1A9. Drug Metab Dispos 29: 407-414, 2001.
12. Mani S: UGT1A1 polymorphism predicts irinotecan toxicity: evolving proof. AAPS Pharm Sci 3: 2, 2001.
13. Nagar S and Blanchard RL: Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan. Drug Metab Rev 38: 393-409, 2006.
14. Innocenti F, Stadler WM, Iyer L, Ramirez J, Vokes EE and Ratain MJ: Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea. Clin Cancer Res 6: 3400-3405, 2000.
15. Boerner SA, Tourne ME, Kaufmann SH and Bible KC: Effect of P-glycoprotein on flavopiridol sensitivity. Br J Cancer 84: 1391-1396, 2001.
16. Nakanishi T, Karp JE, Tan M, et al: Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients. Clin Cancer Res 9: 3320-3328, 2003.
17. Jager W, Zembsch B, Wolschann P, et al: Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver. Life Sci 62: 1861-1873, 1998.
18. D obson PD and Kell DB: Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat Rev Drug Discov 7: 205-220, 2008.
19. Hagenbuch B and Gui C: Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 38: 778-801, 2008.
20. Kim RB: Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur J Clin Invest 33 (Suppl 2): 1-5, 2003.
21. Tamai I, Nezu J, Uchino H, et al: Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 273: 251-260, 2000.
22. Muto M, Onogawa T, Suzuki T, et al: Human liver-specific organic anion transporter-2 is a potent prognostic factor for human breast carcinoma. Cancer Sci 98: 1570-1576, 2007.
23. Wlcek K, Svoboda M, Thalhammer T, Sellner F, Krupitza G and Jaeger W: Altered expression of organic anion transporter polypeptide (OATP) genes in human breast carcinoma. Cancer Biol Ther 7: 1452-1457, 2008.
24. Obaidat A, Roth M and Hagenbuch B: The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. Annu Rev Pharmacol Toxicol 52: 135-151, 2012.
25. Mikkaichi T, Suzuki T, Tanemoto M, Ito S and Abe T: The organic anion transporter (OATP) family. Drug Metab Pharmacokinet 19: 171-179, 2004.
26. Abe T, Unno M, Onogawa T, et al: LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 120: 1689-1699, 2001.
27. Okabe M, Unno M, Harigae H, et al: Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem Biophys Res Commun 333: 754-762, 2005.
28. Ciarimboli G, Ludwig T, Lang D, et al: Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 167: 1477-1484, 2005.
29. Yonezawa A, Masuda S, Yokoo S, Katsura T and Inui K: Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 319: 879-886, 2006.
30. Zhang S, Lovejoy KS, Shima JE, et al: Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 66: 8847-8857, 2006.
31. Svoboda M, Wlcek K, Taferner B, et al: Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport. Biomed Pharmacother 65: 417-426, 2011.
32. Okabe M, Szakacs G, Reimers MA, et al: Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther 7: 3081-3091, 2008.
33. Ni W, Ji J, Dai Z, et al: Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition. PLoS One 5: e13792, 2010.
34. Gui C, Miao Y, Thompson L, et al: Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol 584: 57-65, 2008.
35. Treiber A, Schneiter R, Hausler S and Stieger B: Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos 35: 1400-1407, 2007.
36. Leuthold S, Hagenbuch B, Mohebbi N, Wagner CA, Meier PJ and Stieger B: Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters. Am J Physiol Cell Physiol 296: C570-C582, 2009.
37. Murias M, Miksits M, Aust S, et al: Metabolism of resveratrol in breast cancer cell lines: impact of sulfotransferase 1A1 expression on cell growth inhibition. Cancer Lett 261: 172-182, 2008.
38. Riha J, Brenner S, Bohmdorfer M, et al: Resveratrol and its major sulfated conjugates are substrates of organic anion transporting polypeptides (OATPs): impact on growth of ZR-75-1 breast cancer cells. Mol Nutr Food Res 58: 1830-1842, 2014.
39. Palermo DP, DeGraaf ME, Marotti KR, Rehberg E and Post LE: Production of analytical quantities of recombinant proteins in Chinese hamster ovary cells using sodium butyrate to elevate gene expression. J Biotechnol 19: 35-47, 1991.
40. Unger C, Popescu R, Giessrigl B, et al: An apolar extract of Critonia morifolia inhibits c-Myc, cyclin D1, Cdc25A, Cdc25B, Cdc25C and Akt and induces apoptosis. Int J Oncol 40: 2131-2139, 2012.
41. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ and Fattinger K: Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36: 164-172, 2002.
42. Annaert P, Ye ZW, Stieger B and Augustijns P: Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica 40: 163-176, 2010.
43. Ji J, Mould DR, Blum KA, et al: A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol. Clin Cancer Res 19: 1269-1280, 2013.
44. Wong CC, Akiyama Y, Abe T, Lippiat JD, Orfila C and Williamson G: Carrier-mediated transport of quercetin conjugates: involvement of organic anion transporters and organic anion transporting polypeptides. Biochem Pharmacol 84: 564-570, 2012.
45. Wlcek K, Svoboda M, Thalhammer T, Sellner F, Krupitza G and Jaeger W: Altered expression of organic anion transporter polypeptide (OATP) genes in human breast carcinoma. Cancer Biol Ther 7: 1450-1455, 2008.
46. Carlson BA, Dubay MM, Sausville EA, Brizuela L and Worland PJ: Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 56: 2973-2978, 1996.
47. Baumann KH, Kim H, Rinke J, Plaum T, Wagner U and Reinartz S: Effects of alvocidib and carboplatin on ovarian cancer cells in vitro. Exp Oncol 35: 168-173, 2013.
48. Buxhofer-Ausch V, Secky L, Wlcek K, et al: Tumor-specific expression of organic anion-transporting polypeptides: transporters as novel targets for cancer therapy. J Drug Deliv 2013: 863539, 2013.
49. Seithel A, Eberl S, Singer K, et al: The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab Dispos 35: 779-786, 2007.
50. Matsushima S, Maeda K, Ishiguro N, Igarashi T and Sugiyama Y: Investigation of the inhibitory effects of various drugs on the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 36: 663-669, 2008.
51. Wang X, Wolkoff AW and Morris ME: Flavonoids as a novel class of human organic anion-transporting polypeptide OATP1B1 (OATP-C) modulators. Drug Metab Dispos 33: 1666-1672, 2005.